Bone Biologics - Warrants (13/10/2026) Overview
Valuation check: BBLGW's ROE is -73.66%, below the sector sector average of 11.64%.
Get informed when a big investor buys or sells
+ Follow-73.66%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for BBLGW is -73.66%. That is below the sector sector average of 11.64%. Investors often review this figure alongside Bone Biologics - Warrants (13/10/2026)'s historical trend and sector peers before judging valuation or financial health.
Against its sector companies, BBLGW currently prints -73.66% for ROE, while the sector average sits near 11.64%. That is roughly 733.0% below the sector mean. Large gaps often invite a closer look at Bone Biologics - Warrants (13/10/2026)'s growth, margins, and balance sheet.
Return on Equity shows how effectively Bone Biologics - Warrants (13/10/2026) converts resources into returns. At -73.66%, BBLGW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting BBLGW's ROE (-73.66%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
